Patent 10512620 was granted and assigned to ALTATHERA PHARMACEUTICALS LLC on December, 2019 by the United States Patent and Trademark Office.
This disclosure provides method of safely and efficaciously treating or preventing atrial fibrillation, atrial flutter, or a combination thereof via rapid intravenous introduction of sotalol hydrochloride to a subject in need thereof.